Hercules Capital CEO Manuel Henriquez has voluntarily stepped aside as the firm’s chairman and CEO. According to Bloomberg, the news comes in the wake of Henriquez’s indictment by federal authorities because of his alleged involvement in the college admissions cheating scandal.
Hercules Capital closed a term loan of up to $75 million for Nabriva Therapeutics, a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.
Hercules Capital increased FuelCell Energy’s credit facility to $25 million and extended the maturity date to 2020.
Cell-based medicine developer Mesoblast entered into a $75 million non-dilutive, four-year credit facility with specialty finance company Hercules Capital.
Sorrento Therapeutics, a clinical-stage biopharmaceutical company developing treatments for cancer and other diseases, entered into a loan and security agreement with Hercules Capital for up to $75 million.